Omeros EBITDA 2010-2025 | OMER
Omeros Annual EBITDA (Millions of US $) |
|
---|---|
2024 | $-167 |
2023 | $-162 |
2022 | $-161 |
2021 | $-172 |
2020 | $-155 |
2019 | $-144 |
2018 | $-111 |
2017 | $-43 |
2016 | $-54 |
2015 | $-71 |
2014 | $-70 |
2013 | $-50 |
2012 | $-37 |
2011 | $-27 |
2010 | $-30 |
2009 | $-20 |
Omeros Quarterly EBITDA (Millions of US $) |
|
---|---|
2025-03-31 | $-34 |
2024-12-31 | $-35 |
2024-09-30 | $-35 |
2024-06-30 | $-59 |
2024-03-31 | $-39 |
2023-12-31 | $-39 |
2023-09-30 | $-47 |
2023-06-30 | $-40 |
2023-03-31 | $-36 |
2022-12-31 | $-38 |
2022-09-30 | $-50 |
2022-06-30 | $-37 |
2022-03-31 | $-35 |
2021-12-31 | $-43 |
2021-09-30 | $-40 |
2021-06-30 | $-45 |
2021-03-31 | $-45 |
2020-12-31 | $-17 |
2020-09-30 | $-25 |
2020-06-30 | $-27 |
2020-03-31 | $-23 |
2019-12-31 | $-27 |
2019-09-30 | $-11 |
2019-06-30 | $-9 |
2019-03-31 | $-19 |
2018-12-31 | $-18 |
2018-09-30 | $-35 |
2018-06-30 | $-30 |
2018-03-31 | $-27 |
2017-12-31 | $-14 |
2017-09-30 | $-5 |
2017-06-30 | $-12 |
2017-03-31 | $-13 |
2016-12-31 | $-12 |
2016-09-30 | $-12 |
2016-06-30 | $-11 |
2016-03-31 | $-19 |
2015-12-31 | $-18 |
2015-09-30 | $-19 |
2015-06-30 | $-16 |
2015-03-31 | $-18 |
2014-12-31 | $-20 |
2014-09-30 | $-17 |
2014-06-30 | $-17 |
2014-03-31 | $-16 |
2013-12-31 | $-14 |
2013-09-30 | $-13 |
2013-06-30 | $-13 |
2013-03-31 | $-10 |
2012-12-31 | $-7 |
2012-09-30 | $-13 |
2012-06-30 | $-8 |
2012-03-31 | $-8 |
2011-12-31 | $-10 |
2011-09-30 | $-6 |
2011-06-30 | $-5 |
2011-03-31 | $-6 |
2010-12-31 | $-8 |
2010-09-30 | $-7 |
2010-06-30 | $-7 |
2010-03-31 | $-6 |
2009-12-31 | $-5 |
2009-09-30 | $-4 |
2009-06-30 | $-6 |
2009-03-31 | $-5 |
Sector | Industry | Market Cap | Revenue |
---|---|---|---|
Medical | Medical Products Manufacturing | $0.198B | $0.000B |
Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. |
Stock Name | Country | Market Cap | PE Ratio |
---|---|---|---|
Boston Scientific (BSX) | United States | $152.324B | 38.13 |
Stryker (SYK) | United States | $149.641B | 31.29 |
EssilorLuxottica (ESLOY) | France | $137.721B | 0.00 |
Medtronic (MDT) | Ireland | $114.146B | 16.18 |
Lonza Group Ag (LZAGY) | Switzerland | $51.237B | 0.00 |
Haleon (HLN) | United Kingdom | $45.147B | 25.77 |
ResMed (RMD) | United States | $37.534B | 28.19 |
GE HealthCare Technologies (GEHC) | United States | $34.575B | 16.42 |
Agilent Technologies (A) | United States | $34.457B | 22.46 |
Terumo (TRUMY) | Japan | $25.051B | 32.54 |
Koninklijke Philips (PHG) | Netherlands | $23.235B | 16.30 |
Insulet (PODD) | United States | $20.934B | 82.17 |
Zimmer Biomet Holdings (ZBH) | United States | $18.835B | 12.10 |
Baxter (BAX) | United States | $15.298B | 11.42 |
Smith & Nephew SNATS (SNN) | United Kingdom | $13.441B | 0.00 |
Demant (WILYY) | Denmark | $8.971B | 0.00 |
Sunny Optical Technology (SNPTF) | China | $8.561B | 0.00 |
Bio-Rad Laboratories (BIO) | United States | $6.887B | 23.97 |
Lantheus Holdings (LNTH) | United States | $5.776B | 14.57 |
Prestige Consumer Healthcare (PBH) | United States | $3.897B | 17.41 |
Perrigo (PRGO) | Ireland | $3.742B | 9.48 |
Haemonetics (HAE) | United States | $3.724B | 16.96 |
Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
Envista Holdings (NVST) | United States | $3.454B | 28.70 |
ICU Medical (ICUI) | United States | $3.341B | 24.63 |
QuidelOrtho (QDEL) | United States | $2.135B | 14.68 |
LeMaitre Vascular (LMAT) | United States | $1.910B | 42.70 |
AtriCure (ATRC) | United States | $1.580B | 0.00 |
Acuren (TIC) | United States | $1.397B | 0.00 |
Phibro Animal Health (PAHC) | United States | $1.272B | 16.26 |
Green Thumb Industries (GTBIF) | United States | $1.249B | 28.09 |
AdaptHealth (AHCO) | United States | $1.247B | 12.66 |
Neogen (NEOG) | United States | $1.194B | 15.28 |
BioLife Solutions (BLFS) | United States | $1.068B | 0.00 |
InMode (INMD) | Israel | $0.963B | 9.70 |
Kestra Medical Technologies (KMTS) | United States | $0.791B | 0.00 |
Maravai LifeSciences Holdings (MRVI) | United States | $0.703B | 0.00 |
Tilray Brands (TLRY) | Canada | $0.679B | 0.00 |
Curaleaf Holdings (CURLF) | Canada | $0.670B | 0.00 |
Owens & Minor (OMI) | United States | $0.667B | 5.53 |
Evolus (EOLS) | United States | $0.623B | 0.00 |
CeriBell (CBLL) | United States | $0.596B | 0.00 |
Capricor Therapeutics (CAPR) | United States | $0.522B | 0.00 |
Valneva SE (VALN) | France | $0.502B | 0.00 |
Surmodics (SRDX) | United States | $0.441B | 0.00 |
SNDL (SNDL) | Canada | $0.373B | 0.00 |
VAREX IMAGING (VREX) | United States | $0.347B | 12.77 |
Sanuwave Health (SNWV) | United States | $0.308B | 0.00 |
SEMPERIT AG HLD (SEIGY) | Austria | $0.304B | 0.00 |
Quanterix (QTRX) | United States | $0.295B | 0.00 |
Cresco Labs (CRLBF) | United States | $0.291B | 0.00 |
Cerus (CERS) | United States | $0.285B | 0.00 |
Viemed Healthcare (VMD) | United States | $0.276B | 23.27 |
Sanara MedTech (SMTI) | United States | $0.269B | 0.00 |
ZimVie (ZIMV) | United States | $0.264B | 12.01 |
Brainsway (BWAY) | Israel | $0.246B | 65.00 |
Canopy Growth (CGC) | Canada | $0.232B | 0.00 |
OraSure Technologies (OSUR) | United States | $0.227B | 0.00 |
Biote (BTMD) | United States | $0.225B | 6.34 |
Verano Holdings (VRNOF) | United States | $0.210B | 0.00 |
Organigram Global (OGI) | Canada | $0.193B | 0.00 |
High Tide (HITI) | Canada | $0.190B | 0.00 |
TriSalus Life Sciences (TLSI) | United States | $0.190B | 0.00 |
Utah Medical Products (UTMD) | United States | $0.186B | 15.15 |
Vireo Growth (VREOF) | United States | $0.150B | 0.00 |
Exagen (XGN) | United States | $0.145B | 0.00 |
FitLife Brands (FTLF) | United States | $0.126B | 15.53 |
TerrAscend (TSNDF) | Canada | $0.104B | 0.00 |
MacroGenics (MGNX) | United States | $0.100B | 0.00 |
Fonar (FONR) | United States | $0.096B | 12.37 |
Jin Medical (ZJYL) | China | $0.093B | 0.00 |
Oramed Pharmaceuticals (ORMP) | United States | $0.089B | 0.00 |
Apyx Medical (APYX) | United States | $0.086B | 0.00 |
Quipt Home Medical (QIPT) | United States | $0.082B | 0.00 |
Veru (VERU) | United States | $0.081B | 0.00 |
Jushi Holdings (JUSHF) | United States | $0.072B | 0.00 |
Zynex (ZYXI) | United States | $0.072B | 0.00 |
InterCure (INCR) | Israel | $0.072B | 0.00 |
Agape ATP (ATPC) | $0.071B | 0.00 | |
Cytosorbents (CTSO) | United States | $0.070B | 0.00 |
ImmuCell (ICCC) | United States | $0.061B | 0.00 |
Rockwell Medical (RMTI) | United States | $0.041B | 0.00 |
Nephros (NEPH) | United States | $0.040B | 53.29 |
Modular Medical (MODD) | United States | $0.039B | 0.00 |
United-Guardian (UG) | United States | $0.037B | 12.82 |
Safety Shot (SHOT) | United States | $0.033B | 0.00 |
Allurion Technologies (ALUR) | United States | $0.021B | 0.00 |
INLIF (INLF) | $0.016B | 0.00 | |
IM Cannabis (IMCC) | Canada | $0.014B | 0.00 |
Flora Growth (FLGC) | United States | $0.014B | 0.00 |
Trinity Biotech (TRIB) | Ireland | $0.014B | 0.00 |
Meihua Medical Technologies (MHUA) | China | $0.014B | 0.00 |
Senestech (SNES) | United States | $0.011B | 0.00 |
Cellectar Biosciences (CLRB) | United States | $0.009B | 0.00 |
Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
Akanda (AKAN) | Canada | $0.002B | 0.00 |
Sharps Technology (STSS) | United States | $0.000B | 0.00 |
InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |